Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.67 is 60% above its 5-year average of -1.68, near the high end of its 5-year range (-2.38–-0.67).
38.81% above its 12-month average of -1.09.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.13.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 30 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.67
EARNINGS PER SHARE (EPS) AVG TTM
-1.09
EARNINGS PER SHARE (EPS) AVG 3Y
-1.67
EARNINGS PER SHARE (EPS) AVG 5Y
-1.68
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+38.81%
CURRENT VS 3Y AVG
+59.76%
CURRENT VS 5Y AVG
+60.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Earnings Per Share (EPS)
-0.67
TTM Avg
-1.09
3Y Avg
-1.67
5Y Avg
-1.68
Market Cap
$517.79M
Earnings Per Share (EPS)
-7.58
TTM Avg
-39.00
3Y Avg
-56.28
5Y Avg
-76.67
Market Cap
$519.25M
Earnings Per Share (EPS)
-0.78
TTM Avg
-1.17
3Y Avg
-1.45
5Y Avg
-1.68
Market Cap
$491.93M
Earnings Per Share (EPS)
-0.52
TTM Avg
-0.81
3Y Avg
-1.01
5Y Avg
-1.63
Market Cap
$491.55M
Earnings Per Share (EPS)
-1.98
TTM Avg
-3.65
3Y Avg
-4.15
5Y Avg
-2.79
Market Cap
$547.86M
Earnings Per Share (EPS)
0.01
TTM Avg
0.08
3Y Avg
-2.02
5Y Avg
-4.00
Market Cap
$487.30M
Earnings Per Share (EPS)
-1.99
TTM Avg
-0.88
3Y Avg
-1.91
5Y Avg
-1.95
Market Cap
$551.09M
Earnings Per Share (EPS)
-0.88
TTM Avg
-0.82
3Y Avg
-0.78
5Y Avg
-1.65
Market Cap
$481.33M
Earnings Per Share (EPS)
0.16
TTM Avg
-2.02
3Y Avg
-3.99
5Y Avg
-3.80
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | -0.67 | -1.09 | -1.67 | -1.68 |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -7.58 | -39.00 | -56.28 | -76.67 |
| Altimmune, Inc. (ALT)vs › | $519.25M | -0.78 | -1.17 | -1.45 | -1.68 |
| Evolus, Inc. (EOLS)vs › | $491.93M | -0.52 | -0.81 | -1.01 | -1.63 |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -1.98 | -3.65 | -4.15 | -2.79 |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.01 | 0.08 | -2.02 | -4.00 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -1.99 | -0.88 | -1.91 | -1.95 |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -0.88 | -0.82 | -0.78 | -1.65 |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 0.16 | -2.02 | -3.99 | -3.80 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -1.73 | -1.90 | -1.16 | -1.16 |
Trailing EPS (TTM)
$-0.67
Forward EPS (Est.)
$-0.60
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.87 |
| 2024-12-31 | -1.32 |
| 2023-12-31 | -2.09 |
| 2022-12-31 | -2.38 |
| 2021-12-31 | -1.34 |
| 2020-12-31 | -2.08 |
| 2019-12-31 | -1.83 |
| 2018-12-31 | -2.36 |
| 2017-12-31 | 0.00 |
